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Accumulating evidence indicates that specific triglyceriderich lipoprotein remnants of differing size and composition, such as VLDL, IDL, lipoprotein B-containing particles (LP-B:C, LP-B:C:E, and LP-A-II:B:C:D:E), and markers of triglyceride-rich lipoprotein metabolism such as apolipoprotein C-III (apoC-III), are more related to progression of atherosclerosis than triglycerides per se. 2 In this issue of Circulation, Kugiyama et al 3 present further evidence for the relationship between coronary heart disease and triglyceride-rich lipoproteins, demonstrating in patients with coronary artery disease that remnant lipoprotein levels in the fasting state predict future clinical coronary events independently of other risk factors. This is an important observation because it is consistent with a previous report that showed that calculated IDL plus estimated remnant VLDL as a measure of triglyceride-rich lipoprotein remnants was significantly correlated with the progression of coronary artery disease and clinical coronary events. 4 The assertion by Kugiyama et 20 to 60) and IDLs (S f 12 to 20) seem to share a similar mechanism and potential for penetrating the arterial intima. As such, certain triglyceride-rich lipoproteins are atherogenic, whereas others are not. In particular, small VLDLs and IDLs have been shown to be independently associated with the presence, severity, and progression of atherosclerosis. 4 -10 Serial arterial imaging studies have provided an excellent opportunity to extend cross-sectional associations between triglycerides and coronary heart disease to studies that permit the examination of the relationships between triglyceride-rich lipoproteins and the progression of atherosclerosis. In a subgroup analysis of lipoprotein mass concentrations measured by analytical ultracentrifugation at baseline and after 2 years in the Type II Coronary Intervention Study, change in IDL mass (S f 12 to 20) was significantly predictive of coronary artery lesion progression at 5 years. 5 With the same analytical ultracentrifugation methodology, lipoprotein mass concentrations were measured at baseline and every 6 months for 2 years in 220 subjects participating in the Monitored Atherosclerosis Regression Study (MARS). 6 Lipoproteins in the S f 12 to 60 range (IDLs and small VLDLs) emerged as the independent correlates of coronary artery atherosclerosis progression.
In the same MARS cohort, apoC-III in the LDL-VLDL subfraction was also found to be significantly correlated with coronary artery lesion progression. 11 ApoC-III is a marker of triglyceride-rich lipoprotein metabolism and clearance of VLDLs and chylomicrons. 12 Inhibition of lipoprotein lipaseactivated lipolysis by VLDL-associated apoC-III prolongs the circulatory residence time of VLDL and therefore increases the exposure time of the arterial wall to this atherogenic particle. ApoC-III in VLDL is associated with denser, smaller VLDL subclasses believed to be particularly atherogenic. 13 In a randomly selected subgroup of 63 subjects, lipoprotein particles were isolated by column immunoaffinity techniques. 14 Subjects with coronary artery lesion progression had significantly higher levels of LP-B c (a summed measure of triglyceride-rich lipoproteins) and LP-A-II:B:C:D:E particles of small VLDL and/or IDL-like sizes. 14 LP-A-II:B:C:D:E is a specific triglyceride-rich lipoprotein particle with a low affinity for lipoprotein lipase and a long circulatory residence time that most likely contributes to its atherogenicity. 15 The 3 independent techniques for identifying triglyceriderich lipoproteins outlined above are based on different physical-chemical properties: protein composition (electroimmunoassay for apoC-III), lipoprotein mass (analytical ultracentrifugation), and lipoprotein particles (column immunoaffinity). These results provide compelling evidence for the relationship between the progression of coronary artery atherosclerosis and triglyceride-rich lipoprotein remnants. Other studies, such as the Cholesterol Lowering Atherosclerosis Study and the Program on the Surgical Control of the Hyperlipidemias, have also demonstrated a relationship between coronary artery lesion progression and apoC-III and VLDL, respectively. 16, 17 The aforementioned findings have a particular importance in that triglyceride-rich lipoproteins such as small VLDLs and apoC-III are related to the progression of mild/moderate (Ͻ50% diameter stenosis) rather than severe (Ն50% diameter stenosis) coronary artery lesions. 6, 11 This is relevant to the findings of Kugiyama et al 3 because coronary artery lesions of Ͻ50% diameter stenosis appear to be the lesions that predict clinical coronary events. 18 Triglyceride-rich lipoproteins may contribute to lesion progression, plaque rupture, and clinical coronary events through a variety of mechanisms. Triglyceride-rich lipoproteins are susceptible to peroxidative damage, can be taken up by macrophages directly without oxidative modification to produce foam cells, and are intimately associated with the clotting and fibrinolytic pathways, thus linking atherosclerosis and thrombosis.
Results from the Bezafibrate Coronary Atherosclerosis Intervention Trial 19 and the Lopid Coronary Angiographic Trial, 20 randomized serial coronary angiographic clinical trials that tested bezafibrate and gemfibrozil, respectively, support the growing evidence for the relationship between triglyceride-rich lipoproteins and atherosclerosis. In these trials, a reduction in triglycerides with essentially no change in LDL-cholesterol levels resulted in a reduction in the progression of coronary artery atherosclerosis in both native arteries and aortocoronary bypass grafts to a similar degree as LDL-cholesterol lowering with the HMG-CoA reductase inhibitors. These studies suggest that triglyceride-rich lipoprotein reduction by fibric acid derivatives, perhaps through the downregulation of apoC-III gene expression and reduction in VLDL-associated apoC-III levels, results in the reduction of atherosclerosis progression.
The accumulated literature has consistently indicated triglyceride-rich lipoprotein remnants to be a risk factor for the progression of atherosclerosis and presents plausible mechanisms by which these lipoproteins may be atherogenic and result in clinical coronary events. Small VLDL, IDL, apoC-III, and lipoprotein B-containing particles measured in the fasting state most likely represent specific remnant lipoproteins contained in the fasting remnant lipoprotein immunoaffinity mixed-gel measurement by Kugiyama et al. 3 On the basis of current knowledge concerning the heterogeneity of triglyceride-rich lipoproteins, it is no surprise that several independent measures of specific triglyceride-rich lipoproteins correlate with the progression of atherosclerosis. Each of these specific triglyceride-rich lipoproteins represents one component of the overall remnant particle risk. Although unravelling the complexity of triglyceride-rich lipoproteins will be an ominous task, it has important implications. For example, studies that have reported separation of IDL from LDL have failed to show a relation between LDL and progression of atherosclerosis. 4, 5, 7 Whether there is a single measure or combination of measurements that best represents the triglyceride-rich lipoprotein remnant particle risk of atherosclerosis still needs to be determined, but it is clear that such a pursuit is warranted and well justified.
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